Waystar
Two-engine B2B software network sold to providers. ENGINE 1, subscription: platform and module fees for denial prevention, prior authorisation, patient payments, analytics, and - since Iodine closed 1 Oct 2025 - clinical documentation integrity and appeal-letter generation. $176.287M in Q2 2026, +34.5%. ENGINE 2, volume-based: per-transaction pricing on claims, eligibility and remittance traffic. $142.149M, +2.8% (canon CF-WAY-10). The alternative cut of the same quarter is provider $231.804M (+23%) and patient $87.870M (+7%). Both engines are paid from money the provider RECOVERS - a denial overturned, a claim paid, a patient balance collected - which is the payer-identity property the board owns this name for, and is structurally different from software billed against a hospital IT budget in a year when hospital IT purchasing is under pressure.
The thesis on this name
State of AI for Healthcare
The only near-pure listed way to own the second half of the corrected thesis — software paid out of the provider's OWN collected revenue rather than its IT opex — and the exact name on which the conventional proxy book fails. It passes the payer test: Q2 2026 revenue $319.7M (+18%), net revenue retention 108.3%, subscription revenue $176.3M (+34.5%) against volume-based $142.1M (+2.8%), and 1,453 clients above $100k of LTM revenue (+15%), at $21.11 and a $4.05B market cap — ~49% below the $41.47 52-week high, on 12.2x forward earnings (a third-party consensus estimate, and the load-bearing input). It fails the AI test, which is why the conviction here is deliberately LOW even though the position sheet holds it: the adjusted-EBITDA margin ladder runs 40.6% (FY2024) → 42.0% (FY2025) → 42.8% (Q2 2026) → 43.0% (1H 2026), and the +140bp fiscal-year move is ordinary operating leverage on a scaled payments network in the year 'AI revenue cycle' was the entire story. No Waystar disclosure separates a dollar of AI revenue, so none is asserted. Gross margin is 68–69%, not Doximity's 89.1%; R&D is 5.0% of revenue; Q2 GAAP net margin was 12.8%; unlevered free cash flow halved to 20.0% of revenue from 40.9% a year earlier as NOLs burned off; and 89.3% of the balance sheet is goodwill and intangibles from ten acquisitions since 2018, including the reported $1.25B Iodine Software deal closed 1 Oct 2025. Underwrite it as a cheap revenue-cycle roll-up that happens to sit in the right revenue pool. Booking it as an AI-in-healthcare expression is the substitution that rejects the proxy book.
State of AI for Healthcare
The only listed instrument paid out of the provider's own collected revenue rather than its IT opex line — at 12.2x forward earnings, ~49% below its 52-week high, with subscription revenue compounding 34.5% and Epic's Penny already live at 200+ organisations doing the same job.
State of AI for Healthcare
The only listed instrument paid out of the provider's own collected revenue rather than its IT opex line. ~$21.11 (31 Jul 2026 close), $4.05B market cap, 12.19x forward earnings on a third-party consensus estimate, ~49% below the 52-week high of $41.47. Q2 2026 (reported 29 Jul 2026): revenue $319.7M +18.1%, adjusted EBITDA $136.7M at a 43% margin as the company states it (42.8% on its own disclosed inputs), subscription revenue $176.3M +34.5% against volume-based $142.1M +2.8%, net revenue retention 108%, 1,453 clients above $100k of LTM revenue (+15%), FY2026 guidance raised to $1.276–1.294B of revenue and $535–545M of adjusted EBITDA. Held at one third of the weight the rejected proxy book gives it, and for a different reason: not as 'the AI revenue-cycle name' — no disclosure separates AI revenue or AI margin here, and the FY2024 40.65% to FY2025 42.04% move is +140bp of ordinary operating leverage on a scaled payments network — but as the single listed asset on the correct side of the payer test, with Epic Penny (live at 200+ organisations, doing the same job) expressed as a smaller size rather than an argued-away risk. Two quality caveats sized into the 4%: unlevered free-cash-flow margin was 20.0% of revenue in Q2 2026 against 40.9% a year earlier, and 89.3% of the balance sheet is purchase accounting after the $1.25B Iodine Software acquisition closed 1 Oct 2025.
Earnings, margins, COGS & capex
A scaled, cash-generative, levered roll-up sitting in an unusually good revenue pool and priced as though it sits in a bad one. The pool is the point: providers pay Waystar out of money Waystar helps them COLLECT - overturned denials, cleaner claims, captured patient balances - not out of an IT budget that gets cut when Kaufman Hall says hospital margins are under pressure. That is the payer test the board built its book around, and Waystar is the only listed instrument that passes it cleanly. What it does NOT pass is the AI test, and the evidence is its own ladder: adjusted EBITDA margin went 40.65% (FY2024) to 42.04% (FY2025), +140bp across the exact year 'AI revenue cycle' was the entire narrative and the CEO framed the company as leading healthcare's AI transformation (canon PB-043). A 140bp move on a scaled payments network is ordinary operating leverage - neither new nor AI-attributable - and no disclosure separates a dollar of AI revenue, so none is asserted. Q2 2026 is good on its own terms: revenue $319.7M +18%, subscription +34.5% vs volume-based +2.8%, NRR 108.3%, 1,453 clients above $100k LTM (+15%), guidance raised, leverage 3.0x -> 2.5x. The market sold it 14.6% in a single session. Two things explain that better than the headline: deceleration risk in the fast half as Iodine approaches its Q4 2026 anniversary, and unlevered FCF at 20.0% of revenue against 40.9% a year earlier. Underwrite it as a cheap revenue-cycle network that happens to occupy the right revenue pool, carrying $1.28B of net debt on an 89%-purchase-accounting balance sheet. Booking it as an AI-in-healthcare expression is the substitution that caused the board to reject its own conventional proxy construction (PB-041 / PB-043).
Income statement — where each revenue dollar goes
% of revenueOf every $1 of revenue, ~32¢ is cost of goods and ~0¢ operating expense, leaving ~68¢ of operating profit (~13¢ net).
Revenue trend
Margins
Network economics, not software economics - connectivity, payment rails, hosting and implementation sit in COGS. Iodine guided immediately gross-margin accretive; not yet visible as a sustained TTM step-up
FISCAL-YEAR basis; bottom rung of the four-rung ladder (CF-WAY-05)
+140bp on FY2024, FISCAL-YEAR basis. The move that demoted the AI-attribution framing (CF-WAY-06 / PB-043)
QUARTERLY basis. Print '43% (company-stated; 42.8% on the disclosed inputs)' or the inputs alone - never '43% ($136.7M on $319.7M)', which does not recompute (CF-WAY-07)
HALF-YEAR basis. A true TTM margin is ~43.4%; the FY2026 guide midpoint implies 42.0% (CF-WAY-08)
Non-GAAP net income $83.283M ($0.43 diluted). The 30-point gap to adjusted EBITDA is amortisation, stock comp and interest (CF-WAY-11)
HALVED YoY. Board attributes it to NOL burn-off - the board's reading, not an issuer statement. CFO $59.411M (CF-WAY-14)
Low for anything claiming to be an AI platform; consistent with a distribution-and-network business that buys capability - ten acquisitions since 2018
COGS structure
Two layers, and the split is why gross margin is 68-69% rather than 85%+. LAYER 1, network cost: clearinghouse connectivity to thousands of payer endpoints, processing at roughly 7.5 billion payment transactions a year (company-stated), payment-rail and card-acceptance cost on the patient-payments side, and cloud hosting for a platform touching ~$2.4 trillion of gross claims annually. This layer scales sub-linearly with revenue and is the source of the ~140bp-a-year operating-leverage drift the margin ladder shows. LAYER 2, services and implementation: onboarding a health system onto a claims-and-denials workflow is a professional-services engagement, and clinical documentation integrity (the Iodine capability) carries a clinical-review element that behaves more like services than software. A third cost sits inside these without separate disclosure: inference on the AI features - denial prediction, appeal-letter generation, documentation-gap detection - so its trajectory cannot be tracked from outside. What can be said is that gross margin has stayed in a 68-69% TTM band while the company acquired an asset it called immediately gross-margin accretive; anyone underwriting a step-change to software-like margin is underwriting a claim the printed number has not yet confirmed.
Capex
Not separately verified here and deliberately not derived (see snapshot.capexIntensity). Structurally, capital intensity is acquisition-led rather than asset-led: 89.3% of total assets at 30 Jun 2026 is goodwill plus intangibles from ten acquisitions since 2018, most recently Iodine Software at $1.25B enterprise value (AS REPORTED - CF-WAY-17 flags it as not re-grounded at primary), funded 50/50 cash and stock, closed 1 Oct 2025 from shareholders led by Advent International. Maintenance capital is capitalised software development plus the ongoing cost of payer connectivity; growth capital is M&A. That matters for anyone modelling free cash flow: unlevered FCF of $63.908M in Q2 2026 is struck before the acquisition spend that produced most of the growth.
Latest earnings
Beat and raise on the reported metrics - non-GAAP EPS $0.43 against a consensus around $0.40 (third-party consensus as reported; no primary source exists for a consensus figure) - with FY2026 guidance raised. The market did the opposite of the headline: shares fell 14.60% on 30 Jul 2026, from $24.52 to $20.94 (verified in the price history, which recomputes exactly). The plausible reads are all inference and none is confirmed by the company: deceleration setup in the fast half as Iodine nears its Q4 2026 anniversary, the halving of unlevered FCF margin, and a ~19% run into the print. Recovery was nearly as fast - +7.34%, +4.90%, -1.64%, +1.63% to a $23.76 close on 6 Aug.
FY2026, raised 29 Jul 2026 from $1.274-1.294B revenue / $530-540M adjusted EBITDA: revenue $1.276B-$1.294B, adjusted EBITDA $535M-$545M, non-GAAP net income $322M-$340M, diluted non-GAAP EPS $1.61-$1.70. Implied adjusted-EBITDA margin at the midpoints is 42.0% - BELOW both the Q2 quarter (42.76%) and the 1H half (42.95%) already printed. The company is guiding second-half margin down, which is the least-discussed line in the release.
- Net revenue retention
- 108.3% (release: 108%), Q2 2026 (CF-WAY-12)
- Clients above $100k LTM revenue
- 1,453, +15% YoY (CF-WAY-12)
- Subscription / volume-based split
- $176.287M (+34.5%) / $142.149M (+2.8%), Q2 2026 (CF-WAY-10)
- Adjusted EBITDA margin ladder
- FY2024 40.65% -> FY2025 42.04% -> Q2 2026 42.76% -> 1H 2026 42.95%; FY2026 guide implies 42.0%
- Net debt / leverage
- ~$1.28B; 2.5x TTM adjusted EBITDA of $514.0M, from 3.0x at FY2025 year-end (Q2 release, as relayed)
- Balance-sheet composition
- 89.3% of total assets is goodwill $4,014.8M + intangibles $1,223.9M on $5,868.8M (CF-WAY-15)
- Platform scale
- 30,000+ clients, 1M+ distinct providers, 7.5B+ payment transactions and ~$2.4T gross claims annually, ~60% of US patients, ~1 in 3 hospital discharges (company-stated boilerplate, 2026)
- AI-attributable revenue
- NOT ASSERTED - no disclosure separates it (PB-066 item 3). Any figure claiming otherwise is invented
- Forward P/E
- 12.19x at the board's 31 Jul mark; 13.50x at the 6 Aug quote - a stockanalysis.com consensus estimate in both cases (retrieved 2026-08-02), not an observable, implying forward EPS ~$1.732 (CF-WAY-04)
- Ownership overhang
- IPO 7 Jun 2024 at $21.50, raising ~$968M. Post-IPO stakes were EQT ~29.2%, CPPIB ~22.3%, Bain Capital ~16.8% (as reported, June 2024); subsequent secondary offerings have reduced them and no current figure is asserted here
Growth drivers
- Subscription mix shift — $176.287M growing 34.5% against a volume-based line growing 2.8% (CF-WAY-10). This is the entire re-rate argument: at ~12-13x forward the market prices the blend as the 3% half
- The Iodine attach — 1,000+ hospitals and health systems acquired, stated total addressable market expanded by more than 15%, and cross-sell of clinical documentation integrity into a claims base already touching roughly one in three US hospital discharges (Waystar, 1 Oct 2025, company-stated)
- Net revenue retention 108.3% (release — 108%) with clients above $100k LTM revenue +15% to 1,453 - land-and-expand inside the installed base, which does not depend on new-logo win rates in a soft hospital purchasing year (CF-WAY-12)
- CMS-0057-F - Prior Authorization API compliance date of 1 Jan 2027 for Medicare Advantage, state Medicaid and CHIP FFS, Medicaid and CHIP managed care and FFE QHP issuers, plus 7-calendar-day standard / 72-hour expedited decision clocks live since 1 Jan 2026 (canon REG-PA-001, 89 FR 8758). Forced payer-side interoperability work lands on rails Waystar already operates
- Denial and take-back intensification as secular demand — Waystar has productised the 'silent denials' case from payer payment take-backs (company-stated), the purest expression of a vendor paid to recover somebody else's clawback
- Deleveraging as an equity transfer — adjusted net leverage 3.0x -> 2.5x on $514.0M TTM adjusted EBITDA. With ~22% of enterprise value in debt, EBITDA growth accrues disproportionately to equity even at a flat multiple
Reported financials — SEC EDGAR
Audited GAAP figures pulled from SEC filings · latest filing 2026-02-17. The audited primary-source spine — not financial advice.
Revenue — annual (GAAP)
Margins & balance sheet — FY’25
Bull & bear
The market prices Waystar as a 3%-growth claims clearinghouse with debt. What it owns is a payments network touching ~60% of US patients, where the half of revenue growing 34.5% is sold into an installed base retaining at 108.3% and paid out of money the customer recovers rather than money the customer budgets. At ~12-13x a consensus forward estimate and ~43% below its high, the re-rate needs no AI story, no new product cycle and no market-share win - only that the fast half keeps being the fast half for two more prints.
- The payer test is the edge, and it is structural rather than cyclical. Waystar is paid from recovered revenue - an overturned denial, a collected patient balance - so its budget line survives a margin squeeze that kills IT-opex-funded software. Of the board's entire 17-name pure-play cohort (16 US-exchange-listed plus OTC-quoted Veradigm, Nasdaq-delisted 2024), this is the ONE name on the correct side of that line (canon PB-045, CM-COH-02)
- Mix shift is arithmetic, not narrative. Subscription at $176.287M growing 34.5% is already ~55% of revenue against a volume line growing 2.8%. Hold both rates four quarters and blended growth rises mechanically while the market keeps paying a clearinghouse multiple. That is the whole re-rate: 12.19x forward at the board's mark to ~14x base and ~18x bull (PB-016)
- Retention proves the product is not discretionary: 108.3% NRR and clients above $100k LTM revenue +15% to 1,453, in a year when hospital EHR purchasing decisions fell roughly 40% versus 2024. Customers are expanding spend with Waystar while cutting elsewhere
- The network is a genuine barrier. Payer connectivity across 7.5 billion annual transactions and ~$2.4 trillion of gross claims is years of integrations, certifications and edit rules; an AI-native entrant can build a better denial model far more easily than the rails the denial travels on
- Regulation is dated and mandatory. CMS-0057-F sets 1 Jan 2027 API compliance across Medicare Advantage, Medicaid and CHIP FFS and managed care, and FFE QHP issuers, with decision clocks live since 1 Jan 2026 (REG-PA-001). Deadlines a payer cannot miss create provider-side work Waystar is already positioned for
- Leverage works for the equity from here: 3.0x -> 2.5x in two quarters on $514.0M TTM adjusted EBITDA, guidance raised, GAAP-profitable. With ~22% of enterprise value in debt, flat-multiple EBITDA growth still compounds equity - and a 14.6% single-session drawdown on a beat-and-raise is the kind of price action that creates an entry rather than invalidating a thesis
Waystar is a levered roll-up whose distribution runs through the company most likely to replace it. Epic owns the record at 43.7% of US acute-care hospitals, Penny is already doing the revenue-cycle job at 200+ organisations at zero customer-acquisition cost, and Waystar cannot reach those customers except through the counterparty monetising them. Meanwhile the half that is not being re-rated grows 2.8%, the AI premium is unsupported by any disclosure, cash conversion halved year-over-year, and 89.3% of the balance sheet is purchase accounting. The board's own note is the honest one: this position does NOT survive its own bear case, which is why it is sized at one third of a normal weight.
- The Epic problem has no hedge. Waystar's customers reach it THROUGH Epic-based health systems; Epic sells Penny into the same buyer inside a contract, BAA and security review it already owns, at zero acquisition cost, across 43.7% of US acute-care hospitals. Epic has never taken outside capital and there is no security to short against it (PB-031). A distribution risk you cannot hedge is a sizing problem, not a modelling problem
- The AI premium is unsupported by the issuer's own numbers. FY2024 40.65% -> FY2025 42.04% is +140bp in the year AI revenue cycle was the entire story, with no release attributing a dollar of revenue to AI (PB-043). Ordinary operating leverage was relabelled as an AI margin - and the relabelling is the risk, because the multiple can compress on narrative alone without a single number changing
- Half the company is a utility. Volume-based revenue of $142.149M grew 2.8%, approximately the growth rate of US healthcare transaction volume. No amount of mix shift converts a clearinghouse into a software company; it only moves the weighted average, and the weighted average is what a de-rating hits
- Cash conversion is going the wrong way: unlevered FCF margin 20.0% in Q2 2026 against 40.9% a year earlier (CF-WAY-14), with GAAP net margin 12.78% against a 42.76% adjusted EBITDA margin. The 30-point wedge is amortisation of acquired intangibles, stock compensation and interest - the adjusted number flatters a roll-up by excluding the cost of being one
- The balance sheet is an acquisition ledger: goodwill $4,014.8M plus intangibles $1,223.9M on $5,868.8M of assets, 89.3% (CF-WAY-15), against $1.47B of gross debt and $12.6M of cash. Organic growth cannot be isolated, an impairment is a live tail risk, and the Iodine anniversary in Q4 2026 removes the subscription line's inorganic support just as the comparison gets hard
- Regulation is not only a tailwind. CMS-0057-F standardises part of the seam Waystar is paid to bridge by 1 Jan 2027; Optum owns the competing clearinghouse from inside the payer; and the market has shown what it does with good news - down 14.6% in one session on a beat-and-raise. At the board's 25% bear weight the multiple goes to ~9x forward and the stock is $15
What it is worth
Forward-earnings re-rate on subscription mix shift - explicitly NOT an AI-attribution model (PB-016). The mechanism: at 12.19x the consensus forward estimate on the board's 31 Jul 2026 mark of $21.11, the market prices the whole company as the volume-based processor growing 2.8%; the thesis is that the subscription half growing 34.5% at 108.3% net revenue retention deserves a software multiple, so the blended multiple should rise as the mix does. Target ties on the implied forward EPS of ~$1.732: bull ~18x = $31.17 (target $32, 30%); base ~14x = $24.24 (target $25, 45%); bear ~9x = $15.59 (target $15, 25%). Probability-weighted target $24.60, implied return ~+17% against the $21.11 mark. THE LOAD-BEARING CAVEAT, restated at every printing: the forward P/E is a THIRD-PARTY CONSENSUS ESTIMATE (stockanalysis.com, retrieved 2026-08-02), not an observable, and it carries the largest single scenario weight on the board (CF-WAY-04). A useful cross-check: Waystar's own FY2026 guidance is $1.61-$1.70 of diluted non-GAAP EPS, midpoint $1.655 - so the ~$1.73 implied forward EPS sits ABOVE the company's own full-year guide, meaning the 'forward' multiple is a next-twelve-months or FY2027-weighted estimate rather than a multiple of guided FY2026 earnings. Sizing is deliberately conservative: 4% of NAV = $400,000 long, one third of the 15% weight the board's REJECTED conventional proxy construction gave it (PB-005 / PB-041 / PB-045), entered on a staged ladder - T1 2% on day one against the known Q2 print, T3 completing to 4% on a print where subscription growth still exceeds volume-based growth or into weakness toward the $17.26 low, but only ABSENT a disclosed Epic Penny client loss (PB-047).
$15 (25%
~9x the ~$1.732 estimate). Epic's Penny attaches at renewal - the chokepoint owner selling the same job into the same buyer at zero customer-acquisition cost across 43.7% of US acute-care hospitals - and subscription growth halves. CMS-0057-F's 1 Jan 2027 Prior Authorization API date commoditises part of the seam rather than monetising it. The market prices Waystar as a share donor: a levered roll-up with 89.3% of assets in goodwill and intangibles, $1.47B of gross debt, 68-69% gross margin, 2.8% growth in 44% of revenue, and no disclosed AI line to defend the premium. The 14.6% single-session decline on a beat-and-raise is the shape of a tape that will not extend the benefit of the doubt, and a levered roll-up de-rates faster than an unlevered one.
$25 (45%
the largest single weight and the one most exposed to the consensus-estimate caveat; ~14x the ~$1.732 estimate). Subscription growth decelerates toward 20% as the Iodine contribution anniversaries in Q4 2026, volume-based stays low single digit, and the company compounds mid-teens revenue at roughly the FY2025 42.0% adjusted EBITDA margin - which is also exactly what the FY2026 guide implies at its midpoints. The multiple drifts from ~12x to ~14x forward: a re-rate earned by execution rather than narrative. Epic Penny stays a live threat that never produces a disclosed client loss, cash conversion normalises somewhere between the 20.0% and 40.9% quarterly prints, and the equity compounds with the deleveraging rather than through a multiple event.
$32 (30%
board scenario against the $21.11 mark; ~18x the ~$1.732 consensus forward EPS estimate). Subscription mix carries the company: the documentation-integrity and appeal-letter products acquired with Iodine hold price because they are paid out of recovered revenue rather than an IT budget, the cross-sell into 30,000+ existing clients is real rather than consolidated, subscription growth stays above 30% through and past the Q4 2026 anniversary, and Penny stays confined to Epic-native shops. CMS-0057-F implementation work lands on Waystar's rails into the 1 Jan 2027 compliance date, leverage keeps falling from 2.5x, and the multiple re-rates toward what the fast half deserves rather than what the slow half is worth.
Framing, not a recommendation, and not investment advice. Three things to carry away. FIRST, the board holds this name for the PAYER TEST and nothing else - the single listed asset paid out of the provider's collected revenue rather than its IT opex - and explicitly NOT as 'the AI revenue-cycle name'; the margin ladder killed that framing and cut the weight from 15% to 4% (PB-045 / PB-043). SECOND, the board states plainly that this position does NOT survive its own bear case: if Epic's Penny attaches at renewal across the 43.7% of US acute-care hospitals Epic already holds, Waystar is selling into a base its distribution partner is monetising directly. The Epic risk is priced into the SIZE rather than argued away, which is the honest treatment of a risk with no hedge. THIRD, the price has moved since the board's vintage and the targets have NOT been re-based: at the 6 Aug 2026 close of $23.76 the same probability-weighted $24.60 target implies roughly +3.5%, not +17%. That is arithmetic on a new price against unchanged scenario targets rather than a new view - but a reader comparing this dossier with the board must know which mark each number is stamped to. FALSIFIER (board-stated): Epic Penny named in a disclosed Waystar client loss or a renewal downgrade at a named health system, OR subscription revenue growth falling below volume-based growth for two consecutive quarters - either closes the position. Note the counter-intuitive entry rule: a disclosed Penny client loss STOPS the second tranche rather than making it cheaper (PB-047). What would upgrade this from a tactical 4% to a real position is the one thing that has never happened - Waystar separately reporting AI-attributable revenue with its own gross margin at a scale that moves the consolidated P&L (PB-046). Until then the AI line is a narrative the disclosure does not support.
SWOT
Strengths
- Paid out of the customer's COLLECTED REVENUE, not its IT budget — the one property the board built its book around, and the reason a hospital margin squeeze is a demand signal here rather than a demand risk (PB-016 / PB-031)
- Network scale that is genuinely hard to rebuild — ~7.5 billion payment transactions and ~$2.4 trillion of gross claims a year across 30,000+ clients and 1M+ distinct providers, touching ~60% of US patients and one in three hospital discharges (company-stated). Payer connectivity is a decade of integrations, not a feature
- Demonstrated in-base expansion — NRR 108.3%, clients above $100k LTM revenue +15% to 1,453, subscription compounding 34.5% - growth that does not require winning a competitive RFP in a weak purchasing year (CF-WAY-12 / CF-WAY-10)
- Real disclosed profitability with improving leverage — 42.76% adjusted EBITDA margin, GAAP-profitable at $40.867M, adjusted net leverage 3.0x -> 2.5x in two quarters. Most of the listed health-AI cohort has neither
- A regulatory tailwind it does not have to lobby for — CMS-0057-F's 1 Jan 2027 Prior Authorization API compliance date forces exactly the payer-provider plumbing Waystar already operates (REG-PA-001)
Weaknesses
- Its distribution runs THROUGH the record owner it competes with. Epic holds 43.7% of US acute-care hospitals and its revenue-cycle agent Penny is live at 200+ organisations, acquired at zero customer-acquisition cost inside a contract the health system already signed. This is the risk the board expresses as a smaller position rather than argues away
- The AI story is unverifiable from the disclosure — +140bp of adjusted-EBITDA margin across FY2025 - the year AI revenue cycle was the whole narrative - and nothing in any release attributes a dollar of revenue to AI (PB-043). If the best listed AI-RCM case cannot separate AI economics from scale economics in its own audited disclosure, the AI premium is a press release
- Quality of earnings moved the wrong way — unlevered FCF margin 20.0% of revenue in Q2 2026 against 40.9% a year earlier (CF-WAY-14). Adjusted EBITDA improved while cash conversion halved
- 89.3% of the balance sheet is goodwill and intangibles from ten acquisitions since 2018 (CF-WAY-15), against $1.47B of gross debt and $12.6M of cash. Organic growth cannot be isolated from acquired growth, and an impairment is a live tail risk in a de-rating
- The volume-based half — 44% of Q2 revenue - grows 2.8%, roughly the rate of US healthcare transaction volume itself. Half the business is a utility, and utilities do not earn software multiples no matter what the other half does
Opportunities
- Iodine cross-sell into the claims base — clinical documentation integrity and appeal-letter generation sold to 30,000+ existing clients, with stated TAM expanded more than 15% and 1,000+ hospitals brought in (Waystar, 1 Oct 2025)
- CMS-0057-F implementation revenue — the 1 Jan 2027 API date plus decision clocks live since 1 Jan 2026 create a dated, mandatory workstream for every affected payer, with the provider-side counterpart on Waystar's rails (REG-PA-001)
- Multiple re-rate on mix — at ~12-13x forward the market prices the blend as the 3%-growth clearinghouse. If subscription holds above 30% for a second consecutive quarter past the Iodine anniversary, the software-multiple argument becomes arithmetic rather than narrative (PB-016)
- Deleveraging arithmetic — 2.5x and falling on $514.0M TTM adjusted EBITDA with ~22% of enterprise value in debt means EBITDA growth transfers to equity at a leveraged rate even on a flat multiple
- The denial-and-take-back arms race — as payers automate adjudication and expand take-backs, provider-side automation demand grows structurally; the 'silent denials' product is the cleanest expression of that
- Consolidation optionality both ways — a ~$4.5B independent network in a category where R1 RCM went private at ~$8.9B (TowerBrook and CD&R, closed 19 Nov 2024) is a plausible sponsor target, and Waystar has itself been the acquirer ten times since 2018
Threats
- EPIC PENNY. The chokepoint owner selling the same revenue-cycle job into the same buyer at zero customer-acquisition cost, inside an existing contract, BAA and security review, across 43.7% of US acute-care hospitals. There is no listed security with which to hedge it, and it is the board's named falsifier (PB-016 / PB-031)
- UnitedHealth's Optum, which owns Change Healthcare — the largest competing clearinghouse - and is vertically integrated into the payer side of the very transactions Waystar intermediates. A competitor that is also a counterparty is structurally worse than a competitor that is only a competitor
- Commoditisation via mandated interoperability. CMS-0057-F is a tailwind for implementation work and a threat to the seam: standardised, mandatory prior-authorisation APIs turn part of what Waystar sells into a regulated commodity. The 1 Jan 2027 date cuts both ways and the board's bear case says so
- Subscription deceleration at the Iodine anniversary in Q4 2026. If 34.5% becomes low-20s once acquired revenue is in the base, the mix-shift re-rate weakens at exactly the moment it was meant to be confirmed
- Leverage plus a de-rating — $1.47B of gross debt on a balance sheet 89.3% composed of purchase accounting, in a health-IT tape where the stock is already ~43% off its high and fell 14.6% on a beat-and-raise. Levered roll-ups de-rate faster than unlevered ones
- Health-system financial stress as a two-sided risk — the same pressure that makes the value proposition compelling also slows the discretionary module purchases inside the subscription line. Kaufman Hall's April 2026 read: performance remains under pressure, expense growth continues (canon CM-KH-04)
Moats, dependencies & bottlenecks
Moats
~7.5 billion payment transactions and ~$2.4 trillion of gross claims annually across 30,000+ clients and 1M+ providers, spanning ~60% of US patients and one in three hospital discharges (company-stated). Thousands of payer integrations, certifications and edit rules accumulated over years - the asset a well-funded AI-native entrant cannot rebuild quickly. But Optum/Change already holds it at comparable scale, so it is a barrier to entry, not an exclusivity.
High while the mechanism holds Being paid out of recovered revenue rather than IT opex is the property the board owns this name for (PB-016 / PB-045). Durable because it is structural to the value proposition rather than contractual. The caveat: it protects the CATEGORY, not the VENDOR - Epic's Penny is paid from the same pool.
NRR 108.3% and 1,453 clients above $100k LTM evidence real stickiness: a claims-and-denials workflow is embedded in staffing, training and cash collection, and ripping it out risks the hospital's cash. The switch is much easier when the replacement is already inside the EHR the staff use all day - the Penny vector precisely.
Waystar's own framing for Iodine was combining 'one of the industry's largest financial datasets with one of the largest clinical datasets' (1 Oct 2025) - a differentiated corpus for denial prediction and documentation-gap detection. Held at Medium for one reason: no disclosure demonstrates that the data advantage converts to revenue or margin, and R&D is 5.0% of revenue.
partly self-eroding Running HIPAA-compliant transaction rails at national scale with payer certifications is a real barrier. CMS-0057-F cuts both ways: it forces work onto those rails by 1 Jan 2027 and standardises part of what made them proprietary (REG-PA-001).
real as a capability Ten acquisitions since 2018 culminating in Iodine at $1.25B enterprise value (as reported), 50/50 cash and stock, closed 1 Oct 2025, guided immediately accretive to gross margin and adjusted EBITDA margin and accretive to non-GAAP diluted EPS in 2027. A repeatable integration machine is a capability rivals can also buy, and it turns into an anti-moat when leverage rises or the multiple compresses - which is why 89.3% purchase accounting sits in the weaknesses too.
Dependencies
Distribution chokepoint AND direct competitor Waystar reaches hospital customers through health systems whose system of record is Epic in 43.7% of US acute-care hospitals in 2025 (per the KLAS share report as relayed). Penny is live at 200+ organisations doing revenue-cycle work, sold inside an existing contract at zero customer-acquisition cost. Epic is private, has never taken outside capital, and cannot be hedged with any security (PB-031). This is the position's named falsifier vector.
Counterparty on every transaction Every claim, eligibility check, remittance and prior-authorisation request has a payer on the other end. Payer behaviour - denial rates, take-back aggressiveness, API strategy under CMS-0057-F - simultaneously creates Waystar's demand and defines its technical surface. Optum sits on both sides of this dependency.
Customer solvency and purchasing capacity Kaufman Hall April 2026: performance remains under pressure, expense growth continues (CM-KH-04). The collected-revenue position blunts this for the core, but the discretionary modules inside the 34.5% subscription line are still sold into a stressed budget.
Regulatory driver and commoditisation risk 89 FR 8758, effective 8 Apr 2024: decision clocks of 7 calendar days standard / 72 hours expedited from 1 Jan 2026, and Patient Access / Provider Access / Payer-to-Payer / Prior Authorization API compliance dates of 1 Jan 2027 (REG-PA-001). A mandated standard API is demand for implementation and a threat to proprietary connection value.
$1.47B total debt against $12.6M cash and $179M investment securities; adjusted net leverage 2.5x on $514.0M TTM adjusted EBITDA, improved from 3.0x. Manageable and improving, but it makes the equity a levered claim on a business whose cash conversion halved year-over-year, and it constrains M&A capacity while the multiple stays compressed.
Growth dependency The 34.5% subscription growth rate contains acquired revenue anniversarying in Q4 2026. The bull case requires the attach to be real - cross-sold documentation integrity into the existing base - rather than a revenue line consolidated for four quarters. This is the board's explicit catalyst test (PB-016).
Share supply / overhang IPO 7 Jun 2024 at $21.50 raising ~$968M, with post-IPO stakes reported at EQT ~29.2%, CPPIB ~22.3% and Bain Capital ~16.8%. Subsequent secondary offerings have reduced them; no current stake is asserted here. Residual sponsor holdings are potential supply into any re-rate.
Advantages
- The only listed instrument in the board's 17-name pure-play cohort (16 US-exchange-listed plus OTC-quoted Veradigm, Nasdaq-delisted 2024) paid out of the provider's collected revenue rather than its IT opex line (canon PB-045, CM-COH-02)
- National transaction scale that is hard to replicate — ~$2.4 trillion of gross claims and ~7.5 billion payment transactions annually, ~60% of US patients (company-stated)
- Proven in-base expansion — 108.3% NRR and clients above $100k LTM revenue +15% to 1,453, in a weak hospital purchasing year
- Disclosed GAAP-positive profitability with improving leverage — 42.76% adjusted EBITDA margin, $40.867M GAAP net income, adjusted net leverage 3.0x -> 2.5x
- A dated regulatory catalyst it does not have to create — CMS-0057-F's 1 Jan 2027 Prior Authorization API compliance date
- Claims-plus-clinical data corpus post-Iodine, with 1,000+ hospitals added and stated TAM expanded by more than 15%
Weaknesses
- Distribution runs through Epic, which sells the competing revenue-cycle agent at zero customer-acquisition cost across 43.7% of US acute-care hospitals - and cannot be hedged
- No disclosure separates AI revenue or AI margin — the FY2024 -> FY2025 move was +140bp, ordinary operating leverage relabelled
- Unlevered free-cash-flow margin halved year-over-year to 20.0% of revenue in Q2 2026
- 89.3% of total assets is goodwill and intangibles from ten acquisitions, against $1.47B of gross debt and $12.6M of cash
- Volume-based revenue - 44% of the quarter - grows 2.8%, roughly the underlying transaction-volume rate
- Gross margin of 68-69% and R&D of 5.0% of revenue are network-and-distribution economics, not software economics
- The FY2026 guide implies a 42.0% adjusted-EBITDA margin, BELOW the 42.76% and 42.95% already printed - second-half margin guided down
Bottlenecks
- Epic distribution — Waystar cannot reach a large share of its addressable base except through a private counterparty selling the competing product inside its own contract - a counterparty that cannot be hedged, partnered around, or acquired
- The volume-based half, 44% of Q2 2026 revenue growing 2.8%, drags the blended growth rate down regardless of how fast the subscription line compounds
- The Iodine anniversary in Q4 2026, after which subscription growth must stand on organic cross-sell and the board's 'second consecutive quarter of 30%+' test becomes materially harder
- Cash conversion — unlevered FCF at 20.0% of revenue against 40.9% a year earlier caps how much of the adjusted-EBITDA improvement actually reaches the equity
- Gross margin at 68-69% structurally limits the multiple a mix-shift argument can earn: a network with services cost does not re-rate to a pure-software comparable whatever the growth split looks like
- R&D at 5.0% of revenue is a low ceiling on organically-built AI capability, which forces the roll-up to keep buying and keeps the balance sheet at 89.3% purchase accounting
- Health-system purchasing capacity — hospital EHR purchasing decisions fell roughly 40% versus 2024, and discretionary module sales compete for that same weakened budget
Top signals & trends
Top signals
The mix-shift thesis in one line, and the board's named catalyst. A second consecutive quarter above 30% would confirm the Iodine attach is real rather than consolidated (CF-WAY-10 / PB-016).
The figure that demoted the AI-RCM framing and cut the position from a 15% weight to 4% (CF-WAY-06 / PB-043 / PB-045). Ordinary operating leverage on a scaled payments network.
Verified in the price history, which recomputes exactly on its own percentage chain. The market did not reward the raise. Proximate causes are inference - Iodine anniversary setup, the FCF halving, a ~19% run into the print - and the company has confirmed none of them.
Expansion inside the base in a year when hospital EHR purchasing decisions fell roughly 40% versus 2024 (CF-WAY-12). The metric that says the product is operationally necessary rather than discretionary.
A halving (CF-WAY-14). The board attributes it to NOLs burning off - the board's reading, not an issuer statement. Either way, adjusted EBITDA improved while cash conversion did the opposite.
A raise on both lines (CF-WAY-13) - but the implied full-year margin sits BELOW the 42.76% quarter and 42.95% half already reported, so the guide embeds second-half margin compression.
Deleveraging on a ~22%-debt enterprise value transfers value to equity at a leveraged rate. Carried as relayed from the Q2 release; the arithmetic identities reconcile exactly.
The falsifier vector. The board's trigger is Penny named in a disclosed Waystar client loss or renewal downgrade - with the counter-intuitive rule that such a disclosure STOPS the second tranche rather than making it cheaper (PB-016 / PB-047).
89 FR 8758 (REG-PA-001). Mandatory, dated work on rails Waystar operates - and simultaneously the standardisation of a seam Waystar was previously paid to bridge.
CF-WAY-15 plus the Q2 balance-sheet lines; ten acquisitions since 2018. Do not confuse this 89% with the board's 89% cash weight - two unrelated quantities that appear in adjacent sentences on this board.
Trends
Epic AI Charting reached general availability 4 Feb 2026 and Penny is live at 200+ organisations in revenue cycle. The record owner monetises by SUBSTITUTION - re-addressing the line item inside a contract it already holds - not by charging a toll. For a third-party vendor that is a worse competitive shape than a toll would be.
Provider-side automation demand grows structurally with payer aggressiveness. Waystar has productised the 'silent denials' case from payer payment take-backs - a vendor paid to recover somebody else's clawback is the cleanest expression of the collected-revenue payer position.
1 Jan 2027 API compliance across Medicare Advantage, Medicaid and CHIP FFS and managed care, and FFE QHP issuers; decision clocks live since 1 Jan 2026 (REG-PA-001). Creates dated implementation demand and simultaneously standardises part of the proprietary seam.
R1 RCM went private at ~$8.9B (TowerBrook and CD&R, $14.30 per share, closed 19 Nov 2024) and Change Healthcare sits inside UnitedHealth. A ~$4.5B independent network at ~13x a consensus forward estimate is a plausible sponsor target, which puts a floor under the de-rating case that a pure fundamentals view does not.
Kaufman Hall April 2026: performance under pressure, expense growth continuing (CM-KH-04), with hospital EHR purchasing decisions down roughly 40% versus 2024. Bullish for the collected-revenue core, bearish for discretionary module attach.
Commure carries a $7B mark set by a $70M round in May 2026 (the reporting states neither pre- nor post-money) - a negotiated mark, not a clearing price - against Waystar's ~$4.5B market cap at the 6 Aug 2026 close (the 31 Jul 2026 vintage mark is $4.05B), and sits on the same correct side of the payer test (canon CM-PRIV-CM-01; PB-037). If an AI-native operator's S-1 ever shows the RCM layer earning AI economics, it re-rates Waystar in whichever direction it lands.
Waystar is ~43% below its 52-week high at the 6 Aug close (~49% at the board's 31 Jul mark), and the board's other long, Doximity, is ~73% off its own high. Further sector-wide compression hits both regardless of the payer-identity distinction (PB-031).
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
Hosting and inference for a platform processing ~7.5 billion payment transactions a year (company-stated); consumed as opex inside a 68-69% gross margin and not separately disclosed. Azure = MSFT, GCP = GOOGL.
card networks and acquiring banks The patient-payments line ($87.870M in Q2 2026, +7%) carries interchange and processing cost a pure-software vendor does not - a structural reason gross margin sits below software comparables.
Epic, Oracle Health, MEDITECH, athenahealth and others are the systems Waystar must read from and write to - simultaneously the technical dependency and, for Epic and athenahealth, the competitor. The defining asymmetry of this business.
Thousands of payer connections, certifications and edit rules. The accumulated integration estate is the network moat - and the thing CMS-0057-F partly standardises by 1 Jan 2027.
Acquired technology (ten acquisitions since 2018) Capability is largely bought rather than built - R&D is 5.0% of revenue and 89.3% of assets is goodwill and intangibles. Most recently Iodine Software at $1.25B enterprise value (as reported), 50/50 cash and stock, closed 1 Oct 2025.
The enterprise core, including Iodine's 1,000+ hospitals and health systems and 16 of the 20 institutions on the US News Best Hospitals list (company-stated). The platform touches roughly one in three US hospital discharges.
The long tail of the 30,000+ client base and 1M+ distinct providers. Higher churn, lower ACV, and the segment where athenahealth's bundled model competes most directly.
1,453 as of Q2 2026, +15% YoY (CF-WAY-12) - the disclosed proxy for enterprise penetration and the cleanest evidence of land-and-expand.
$87.870M of Q2 2026 revenue (+7%) from patient financial engagement - estimates, statements, collections. Grows with high-deductible plan design and is the part of the business most exposed to household financial stress.
behavioural health, home health and specialty providers Adjacent verticals reached over the same rails, where competitive intensity is lower than in acute care and the EHR incumbent is usually not Epic.
PRIVATE and permanently uninvestable - never took outside capital. The real competitor, and not on price: 43.7% of US acute-care hospitals and 56.9% of beds in 2025, up from 42.3% (per the KLAS US acute-care EHR share report as relayed - a fifth consecutive year of gains), with Penny live at 200+ organisations doing revenue-cycle work inside a contract, BAA and security review Epic already owns, at zero customer-acquisition cost. Reported ~$6.7B of 2025 revenue (company-stated to Becker's, 28 Apr 2026 - unaudited and unverifiable because Epic files nothing). The board's named falsifier for this position, and unhedgeable.
Owns the largest competing clearinghouse and sits on the PAYER side of the transactions Waystar intermediates - a competitor that is simultaneously a counterparty, with a balance sheet Waystar cannot match. Vertically integrated across payer, provider and payments.
PRIVATE since 19 Nov 2024 - taken out by TowerBrook Capital Partners and Clayton, Dubilier & Rice at $14.30 per share, valuing it at ~$8.9B. The closest scaled competitor in end-to-end revenue-cycle management, now sponsor-owned and free to invest without quarterly scrutiny. Its take-out valuation is also the most relevant private-market comparable for Waystar's own ~$4.5B public mark.
PRIVATE. Payer-founded clearinghouse and the other large independent provider-payer network; its ownership roots in the health plans give it payer-side connectivity advantages and a structurally different pricing incentive. Direct overlap with Waystar's eligibility, claims and prior-authorisation traffic.
PRIVATE (Clearlake-backed). Revenue-cycle platform competing across eligibility, claims management, denials and patient access, aimed at the same hospital and health-system buyer. Smaller and without the payments-network scale, but a persistent RFP presence and a consolidation vehicle in its own right.
PRIVATE. End-to-end revenue-cycle OUTSOURCER rather than a software vendor - it takes over the function instead of tooling it. Where Ensemble wins, Waystar software may still sit underneath but the customer relationship and the pricing power move to the outsourcer. Periodically-reported IPO ambitions are not verified here and no listing is assumed.
Health division of a listed UK credit bureau, competing in patient access, eligibility, identity, estimates and claims. Structural advantage: consumer-identity and credit data Waystar does not own. Structural disadvantage: healthcare payments is a division, not the company. London-listed - named for completeness, not as a US-listed alternative.
PRIVATE (Bain Capital and Hellman & Friedman). Bundles revenue-cycle services with its ambulatory EHR, making it the ambulatory analogue of the Epic threat: the record owner selling the billing service inside the same contract. Overlaps Waystar most in physician practices and smaller groups rather than acute care.
PRIVATE. $7B on a $70M round led by General Catalyst, May 2026 (the reporting states neither pre- nor post-money) - a negotiated mark, not a clearing price - with 500+ healthcare organisations across 3,000+ sites of care. The widely-quoted ~$750M raised conflates equity with a $200M non-dilutive General Catalyst Customer Value Fund repaid from acquired-customer revenue, so no clean equity total is carried (canon CM-PRIV-CM-01, CM-PRIV-CM-02; PB-037). AI-native, on the same correct side of the payer test, and the highest-signal IPO on the board's slate: its S-1 would be the first genuinely AI-native disclosure of whether the RCM layer earns AI economics or merely healthcare economics.
Listed US provider of RCM software and outsourced services focused on community and rural hospitals - the segment Waystar reaches through volume rather than enterprise relationships. Materially smaller and differently positioned, but a listed read-through on pricing and demand at the small-hospital end of the same market.